Supreme Group said the deal deepens its expertise in rare disease and pharma and expands the creative and omnichannel ...

“We’ll be putting initially a small tariff on pharmaceuticals but in one year—one and a half years maximum—it’s going to go ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

The company has launched the ad campaign with three patient ambassadors: Brian, Jeanette and Jennifer, each of whom is ...

BioMarin revealed topline results for the early-stage candidate, BMN 333, that suggest it is a “potentially superior version ...

Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on TV ads for prescription drugs reached a low not seen since this time last ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a ...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...

After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80 ...

After Y-mAbs Therapeutics won its first FDA approval more than 4 years ago, the company has faced numerous hurdles on its quest to become an oncology powerhouse. | More than 4 years after its first ...